MARKET WIREYahoo Finance • 8h ago
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)Yahoo Finance report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
Why AXGN Stock slipped -0.52% Today — RQD Quant Desk Flash
$49.37 -0.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $49.23
Axogen Inc. (AXGN) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $2.96B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AXGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AXGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Axogen Inc. (NASDAQ: AXGN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $49.37 (-0.52% 1D, market cap $2.96B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, AXGN ranks #242 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AXGN compare to TMDX and ITGR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), AXGN carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of 74.3%, and ROIC of -2.6%. By comparison, TMDX (TransMedics Group Inc.) holds a C grade (62/100 RQD, P/E 12.2x, ROIC 18.1%, cap $2.33B) and ITGR (Integer Holdings Corporation) posts a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AXGN?
▼
Per AXGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000805928), Axogen Inc. generated $225.2M in revenue (+20.2% YoY), -$15.7M in net income, and -$2.9M in free cash flow against $221.7M in total assets and $48.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $49.23 (-0.28%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AXGN)Realized 20D OHLCV Swing Band: ±8.8%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY AXGN SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (31% of score)
20D Institutional Volume Accumulation (±8.8% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)
Altman Z-Score 18.64 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$36.17+0% Next Q
46
Q2 (-2Q)Grade D$36.17+3.6% Next Q
49
Q3 (-1Q)Grade C-$37.46+31.8% Next Q
51
CurrentGrade D+$49.37-0.7% Hist 90D α
54
Trajectory: D (46) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AXGN Turnaround Squeeze
While AXGN currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($42.85) and Max Pain ($51.84) forces dealer call-delta covering toward $57.21.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AXGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AXGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AXGN Stock slipped -0.52% Today — RQD Quant Desk Flash
Axogen Inc. (AXGN) slipped -0.52% to $49.37, trading at 89% of its 52-week range ($21.93 – $52.91). Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 89% of its 52-week range ($21.93 – $52.91) with RSI-14 at 74.3 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.8% around $49.37 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 74.3% gross margin and $0 annual free cash flow.
Live AXGN Headlines & Catalysts
MARKET WIREMoomoo • 11h ago
AxoGen(AXGN) Stock Options Chain | Quotes & NewsMoomoo report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 14h ago
Axogen: Taking The Friction Out Of Nerve Repair (NASDAQ:AXGN)Seeking Alpha report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 17h ago
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?Yahoo Finance report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 20h ago
Axogen, Inc. Stock 12‑Month Price Target Raised to $54, Implies 44% UpsideTradingView report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 23h ago
Earnings Flash (AXGN) Axogen, Inc. Posts Q3 Adjusted EPS $0.21 per Share, vs. FactSet Est of $0.13www.marketscreener.com report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Axogen (AXGN) Stock Price Ignores Q3 Earnings Turn To ProfitSimply Wall St report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
Axogen (AXGN) Q3 2026 Earnings Call TranscriptThe Globe and Mail report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 2d ago
GeneDx Holdings And 2 Other Top Healthcare StocksAI giants are planning up to US$828b in data center and chip spending this year, and that level of capital tied up in one corner of the market has many investors rethinking concentration risk. Capital that chases one sto
CATALYSTSeekingAlpha • 3d ago
Axogen: Taking The Friction Out Of Nerve RepairAxogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next...
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AXGN)
- ✓Walkthrough of AXGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AXGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +15.81%▼ DESCENDING CHANNEL
2026-11-02O $49.25H $49.63L $49.25C $49.37VOL 2.28M
RES: $51.04SUP: $33.66SMA50: $42.85SMA200: $39.76
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AXGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
11.2%/yr Implied 5Y Growth
vs. +20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AXGN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AXGN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AXGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AXGN)
Health Care Rank #242 of 1016
⚔️ TMDX vs AXGN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AXGN vs. TMDX, ITGR, LIVN, CNMD)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Axogen Inc. (AXGN) ranks #242 by composite RQD confidence (54/100, grade D+) and #209 by equity capitalization ($2.96B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. LIVN currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with AXGN at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AXGN
ACTIVE
Axogen Inc. | D+ | 54/100 | — | 74.3% | -2.6% | -0.52% | $2.96B | Benchmark Subject |
| TMDX TransMedics Group Inc. | C | 62/100 | 12.2x | 59.9% | 18.1% | -1.68% | $2.33B | /tmdx-vs-axgn → |
| ITGR Integer Holdings Corporation | C+ | 67/100 | 41.8x | 27.0% | 6.0% | +0.06% | $4.30B | /itgr-vs-axgn → |
| LIVN LivaNova PLC | C+ | 68/100 | — | 67.7% | 17.3% | -2.81% | $4.48B | /livn-vs-axgn → |
| CNMD CONMED Corporation | C | 65/100 | 28.9x | 54.6% | 7.8% | -3.13% | $1.36B | /cnmd-vs-axgn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000805928In its most recent audited fiscal period (FY2025, filed 2025-12-31), Axogen Inc. (AXGN) reported GAAP revenue of $225.2M (+20.2% vs. FY2024 revenue of $187.3M , and +41.6% cumulative change since FY2023) , GAAP net income of -$15.7M, operating cash flow of $812.0K, and free cash flow of -$2.9M (-304.5% YoY). On the balance sheet, AXGN closed FY2025 with $221.7M in total assets against $48.4M in total debt (Altman Z-Score: 18.64, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $225.2M | -$15.7M | $812.0K | -$2.9M | $221.7M | $48.4M |
| FY2024 (FY) | 2024-12-31 | $187.3M | -$10.0M | $4.5M | $1.4M | $203.7M | $47.5M |
| FY2023 (FY) | 2023-12-31 | $159.0M | -$21.7M | -$5.7M | -$12.9M | $1.63B | $381.5M |
3. AXGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AXGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Axogen Inc. (NASDAQ: AXGN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $49.37 (-0.52% 1D, market cap $2.96B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, AXGN ranks #242 in composite RQD confidence.
How does AXGN compare to TMDX and ITGR in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), AXGN carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of 74.3%, and ROIC of -2.6%. By comparison, TMDX (TransMedics Group Inc.) holds a C grade (62/100 RQD, P/E 12.2x, ROIC 18.1%, cap $2.33B) and ITGR (Integer Holdings Corporation) posts a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AXGN?
Per AXGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000805928), Axogen Inc. generated $225.2M in revenue (+20.2% YoY), -$15.7M in net income, and -$2.9M in free cash flow against $221.7M in total assets and $48.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AXGN trading relative to its 50-day, 200-day, and 52-week technical levels?
AXGN last traded at $49.37 (-0.52% on volume of 1,835,218 shares), positioning the stock +15.22% above its 50-day simple moving average ($42.85) and +24.17% above its 200-day simple moving average ($39.76). Across its 52-week range of $21.93 to $52.91, AXGN sits at the 88.6% percentile with a 14-day RSI of 74.3 (OVERBOUGHT (>70)) and an implied next-earnings move of ±8.8% ($45.03 to $53.71).
AXGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AXGN stock moving today?
Why AXGN Stock slipped -0.52% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 54/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AXGN — Axogen Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:24:26Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AXGN scores 54 out of 100, earning a D+ and the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
- Fundamental Cash Engine: 7 / 20. This is the weakest pillar and reflects ROIC of -2.6% and an FCF yield of -0.1%. For an investor, this means the business is not currently generating returns on invested capital or free cash that would support the share price on cash-flow grounds.
- Whale 13F Flow: 17 / 20. This is the strongest pillar, reflecting institutional accumulation and options positioning. It indicates professional money has been building exposure, which is a supportive signal even though the fundamentals do not yet match.
- Insider Conviction: 6 / 20. This is a weak reading based on SEC Form 4 and Congressional PTR cluster flow. Insider signals do not offer strong confirmation of management conviction.
- Macro Regime Fit: 10 / 20. With beta of 1.1 and sector sensitivity, the stock carries roughly market-level volatility, and the rating treats its macro fit as middling.
- Forensic Balance Sheet: 14 / 20. Altman Z of 18.64, Piotroski F of 6/9, and Debt/Equity of 0.38 point to a relatively sound balance sheet on the forensic measures.
Put together, the rating describes a company with a sound balance sheet and strong institutional interest, offset by weak profitability, negative cash returns, and weak insider signals. Potential upside drivers are the institutional accumulation and a balance sheet that does not appear to be the binding constraint. The valuation tradeoff is that the stock trades at a forward P/E of 18 against negative trailing EPS of -0.26, so the price depends on earnings improving from current levels. The rating's verdict suggests the current evidence favors trimming rather than adding.
Business
Axogen Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the company profile, the company's market capitalization is $3.0B. The source data does not describe its products, customers, or revenue model beyond sector and industry classification and reported revenue figures.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $225.2M | $-7.8M | $-15.7M | N/A | $-2.9M | $35.5M | $48.4M |
| FY 2024 | $187.3M | $-3.3M | $-10.0M | N/A | $1.4M | $27.6M | $47.5M |
| FY 2023 | $159.0M | $-21.5M | $-21.7M | N/A | $-12.9M | N/A | $381.5M |
Per the SEC financials, revenue grew from $159.0M in FY 2023 to $225.2M in FY 2025, while the company remained loss-making at the operating and net levels in each period. Per the market data, gross margin is 74.3%, operating margin is -3.5%, and net margin is -7%, with ROIC at -2.6%. Per the Roarable RQD rating, the Altman Z-Score is 18.64 and the Piotroski F-Score is 6/9, and Debt/Equity is 0.38. Reported debt fell from $381.5M in FY 2023 to $48.4M in FY 2025, and cash rose to $35.5M over the same period.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the headlines cover a range of items:
- Price action (YELLOW): A Yahoo Finance report headlined a 22.6% decline over four weeks, framing it as a buying opportunity.
- Options and positioning (YELLOW): A Moomoo report covers the AXGN options chain.
- Thesis coverage (YELLOW): A Seeking Alpha piece frames Axogen around nerve repair.
- Relative performance (GREEN): A Yahoo Finance piece asks whether AXGN is outperforming other medical stocks this year.
- Price target (GREEN): A TradingView report covers a 12-month price target raised to $54, implying 44% upside.
- Earnings (YELLOW): A MarketScreener flash reports Q3 adjusted EPS of $0.21 per share versus a FactSet estimate of $0.13.
Per the butterfly supply-chain graph, no supply-chain links or proprietary signals are available. Risk watch items include the sharp four-week decline noted in the news feed and the gap between reported GAAP losses and the adjusted EPS cited in the earnings flash.
Open Questions
- What drove the FY 2025 net loss of $-15.7M, and what is the path to positive operating income?
- What is the source of the $381.5M FY 2023 debt balance and its reduction to $48.4M by FY 2025?
- Why is trailing P/E unavailable while forward P/E is 18, and what earnings trajectory underlies that estimate?
- What are the holder-level details behind the Whale 13F and insider pillar scores?
- What products and customers generate the reported $225.2M in FY 2025 revenue?
AXGN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Axogen Inc. (AXGN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 8h ago
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN) Yahoo Finance report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 11h ago
AxoGen(AXGN) Stock Options Chain | Quotes & News Moomoo report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 14h ago
Axogen: Taking The Friction Out Of Nerve Repair (NASDAQ:AXGN) Seeking Alpha report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 17h ago
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year? Yahoo Finance report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 20h ago
Axogen, Inc. Stock 12‑Month Price Target Raised to $54, Implies 44% Upside TradingView report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 23h ago
Earnings Flash (AXGN) Axogen, Inc. Posts Q3 Adjusted EPS $0.21 per Share, vs. FactSet Est of $0.13 www.marketscreener.com report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Axogen (AXGN) Stock Price Ignores Q3 Earnings Turn To Profit Simply Wall St report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Axogen (AXGN) Q3 2026 Earnings Call Transcript The Globe and Mail report covering Axogen Inc. (AXGN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AXGN Bull vs. Bear Conversation Board — What's Your Call at $49.37?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AXGN 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $53.60 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AXGN (D+ • RQD 54/100) a Buy at $49.63?
Welcome to the AXGN (Axogen Inc.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Electromedical & Electrotherapeutic Apparatus. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $38.22 (-23.0%)
Spot @ $49.63 Pump the brakes on AXGN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AXGN, but look at what you are paying: current EV/EBITDA multiples with 74.3% gross margins. Unless Axogen Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $62.53 (+26.0%)
Spot @ $49.63 AXGN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AXGN, the market is fixating on short-term headline noise in Biotechnology: Electromedical & Electrotherapeutic Apparatus and ignoring the balance sheet and cash flow trajectory. At $49.63 (52-wk range $21.93 - $52.91), any beat on forward guidance forces shorts and underweight funds to chase.